Skip to content

Clinical trials

Cholangiocarcinoma trials in Hong Kong

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Cholangiocarcinoma Country / region: Hong Kong Clear all

12 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20121
20142
20151
20171
20191
20202
20221
20232
20251

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed6
Active, not recruiting3
Recruiting2
Terminated1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Chinese University of Hong Kong2
Taiho Oncology, Inc.2
Alentis Therapeutics AG1
Arbele Pty Ltd1
AstraZeneca1
Elevar Therapeutics1
Eli Lilly and Company1
Hoffmann-La Roche1
MacroGenics1
Merck Sharp & Dohme LLC1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Cholangiocarcinoma12
Breast Neoplasms3
Pancreatic Neoplasms3
Bile Duct Neoplasms2
Carcinoma, Non-Small-Cell Lung2
Colorectal Neoplasms2
Gallbladder Neoplasms2
Klatskin Tumor2
Melanoma2
Ovarian Neoplasms2

Trials

Showing 76 to 12 of 12. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.